{
  "id": 6137058,
  "title": "Novo Nordisk: STEP Young Phase 3 Trial With Semaglutide Shows Superior BMI Reduction At Week 68",
  "url": "https://urgent.news/2026/09/07/novo-nordisk-step-young-phase-3-trial-with-semaglutide-shows-superior",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-07T12:10:16.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/novo-nordisk-step-young-phase-3-trial-semaglutide-shows-superior-bmi-reduction-week-68"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Novo Nordisk (NVO, NOVOB.CO, NOV.DE) announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years old with obesity. The res",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}